Navidea Biopharmaceuticals' decision to reject the acquisition offer from ProPhase Labs indicates that they believe their assets are worth more than the offer. This could potentially lead to a higher offer or other interested buyers, but in the short term, it's unlikely to have a significant impact on the stock price.

ProPhase Labs' failed acquisition attempt could indicate a setback in their expansion or diversification plans. However, it's also possible they could make a higher offer or seek other acquisition targets. In the short term, this news is unlikely to significantly impact the stock price.